Recently, the Poliovirus receptor-related 2 (PVRL2)-Poliovirus receptor-related immunoglobulin (Ig) domain containing (PVRIG) pathway and the Poliovirus receptor (PVR)-T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) pathway have been focused on as potential new targets for cancer immunotherapy (10). This evidence concerns the gene PVR and cancer.